Vistagen announced the broadening of its intellectual property portfolio after receiving multiple new patents related to the use of PH80 for the treatment of migraine. PH80 is a non-systemic, hormone-free investigational pherine nasal spray in development as a rapid-onset treatment for vasomotor symptoms due to menopause, with the potential to also treat premenstrual dysphoric disorder, dysmenorrhea, and migraine.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTGN:
- Biotech Alert: Searches spiking for these stocks today
- VistaGen Therapeutics Inc. at Risk: Market Turmoil and Economic Instability Threaten Financial Stability
- Vistagen reports FY24 EPS ($1.52) vs. ($8.51) last year
- Options Volatility and Implied Earnings Moves Today, June 11, 2024
- Options Volatility and Implied Earnings Moves This Week, June 10 – June 13, 2024